Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.
CAS Registry Number
53-19-0
Molecular formula
C14H10Cl4
Molecular weight
320 g/mol
Drug class
Adrenocortical cytotoxic and adrenolytic agentsteroidogenesis inhibitor
Mechanism of action
The precise molecular mechanism is not fully understood. Mitotane has selective cytotoxic and adrenolytic effects on adrenal cortical tissue and suppresses steroid synthesis, including cortisol production. It can alter hepatic drug-metabolising enzymes and steroid-binding proteins.
Indications / reported uses
Treatment of patients with inoperable, functional or nonfunctional adrenocortical carcinoma (ACC) under the US LYSODREN indication; requires specialist monitoring of plasma mitotane levels, adrenal function and toxicity
Phase IPhase II where requiredEU / UK / other marketsRequest basket0
ERA assessment scope
Project-specific environmental risk assessment support
The pathway is agreed for the medicinal product, intended market, use assumptions and available environmental evidence.
Phase I exposure screening and trigger evaluation.
Environmental fate and ecotoxicity review, with Phase II work where required.
PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant.
Data-gap review and a report documenting evidence, assumptions, uncertainties and conclusions within the agreed scope.
Assessment scope
Environmental Risk Assessment (ERA)
ReguSight provides project-specific support for the Mitotane Environmental Risk Assessment (ERA) (the Mitotane ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.
Assessment may cover
Product, active-substance identity, formulation, route and intended-market review.
Phase I environmental exposure screening and applicable trigger evaluation.
Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
Data-gap analysis, study strategy, assumptions and scientific reporting.
The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.